Fiduciary Group LLC reduced its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 99,666 shares of the company’s stock after selling 1,051 shares during the period. Johnson & Johnson accounts for approximately 2.3% of Fiduciary Group LLC’s holdings, making the stock its 7th biggest position. Fiduciary Group LLC’s holdings in Johnson & Johnson were worth $17,606,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. Ieq Capital LLC raised its holdings in shares of Johnson & Johnson by 5.1% during the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after acquiring an additional 6,154 shares during the period. RFG Advisory LLC raised its holdings in shares of Johnson & Johnson by 2.7% during the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after acquiring an additional 594 shares during the period. Willis Investment Counsel increased its stake in Johnson & Johnson by 0.4% in the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after buying an additional 1,358 shares during the period. Wambolt & Associates LLC increased its stake in Johnson & Johnson by 2.5% in the 4th quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock valued at $2,566,000 after buying an additional 355 shares during the period. Finally, FDx Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.3% during the 3rd quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock worth $8,237,000 after purchasing an additional 153 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Trading Down 0.8 %
JNJ opened at $161.05 on Wednesday. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The company has a 50-day simple moving average of $158.62 and a 200 day simple moving average of $166.91. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $418.53 billion, a price-to-earnings ratio of 33.69, a P/E/G ratio of 2.78 and a beta of 0.53.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is currently 94.56%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.20% of the company’s stock.
Analyst Upgrades and Downgrades
JNJ has been the subject of several recent analyst reports. UBS Group initiated coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective for the company. Morgan Stanley increased their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a report on Wednesday, April 19th. Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective for the company. Piper Sandler dropped their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Finally, SVB Leerink dropped their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $173.00.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
